Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Rilpivirine (Edurant®) is recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load ≤ 100,000 HIV-1 RNA copies/ml, in combination with other antiretroviral medicinal products. |
|||
|
|||
Medicine details |
|||
| Medicine name | rilpivirine (Edurant®) | ||
| Formulation | 25 mg film-coated tablet | ||
| Reference number | 557 | ||
| Indication | In combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment naïve adult patients with a viral load ≤ 100,000 HIV-1 RNA copies/ml |
||
| Company | Janssen-Cilag Ltd | ||
| BNF chapter | Infections | ||
| Assessment type | Full | ||
| Status | Recommended | ||
| Advice number | 1312 | ||
| NMG meeting date | 15/05/2012 | ||
| AWMSG meeting date | 20/06/2012 | ||
| Ratification by Welsh Government | 23/07/2012 | ||
| Date of issue | 27/07/2012 | ||
| Date of last review | November 2022 | ||
| Further information In November 2024, the licence for rilpivirine (Edurant) was extended to include the treatment of HIV-1 in paediatric patients weighing at least 25 kg without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, and with a viral load ≤ 100,000 HIV‑1 RNA copies/ml. Health boards in Wales should also make this product available for prescribing for this patient population in accordance with the AWMSG policy statement on paediatric licence extensions. Prescribers should also note that the licensed indication for rilpivirine (Edurant) has been refined and updated and this medicine should be prescribed according to its current indication as defined in the Summary of Product Characteristics. |
|||